At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Affera Platform (device)
- How long the study runs
- Study runs about 55 months (dates as stated)
- About the drug or intervention
- Affera Platform — device: A cardiac ablation will be performed using the Affera Platform
- Patient visit burden
- Not specified by the sponsor
In plain English
This is a global registry (a type of study that collects information over time) for people with atrial fibrillation, a condition where the heart beats in an irregular rhythm. It is run by Medtronic Cardiac Ablation Solutions, the company that makes the Affera Platform.
Who can take part
- Adults aged 18 or over, or the minimum age allowed by local rules
- You are due to have a procedure using the Affera Platform, which is already available for normal use
- You are willing and able to follow the study requirements and give your written agreement (consent) to take part, in line with your hospital's and local rules
Who may not be able to
- You are already taking part in another study that has not been approved for joining at the same time by the global study manager
- You meet any exclusion rules set by local law
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about the number of visits, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 540
- Started
- 2023-12-22
- Last checked
- 2025-10
Plain English Summary
What is this study?
- • Testing a new treatment for atrial fibrillation
- • Clinical study - 540 participants
- • The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with atrial fibrillation
Where?
- • Cambridge - Royal Papworth Hospital NHS Foundation Trust
- • London - Imperial College Healthcare NHS Trust - Hammersmith Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to describe clinical performance and safety data in a broad patient population treated with the Affera Platform.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ by local regulations
What the study is looking for
- ✓Subject is ≥ 18 years of age or minimum age as required by local regulations
- ✓Planned procedure using the commercially available Affera Platform
Who cannot take part
- ✗Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study...
- ✗Subject with exclusion criteria required by local law
See the full criteria
Where Is This Study? (2 UK sites)
Royal Papworth Hospital NHS Foundation Trust
Cambridge CB2 0AY, United Kingdom
Imperial College Healthcare NHS Trust - Hammersmith Hospital
London W12 0HS, United Kingdom